Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) Given Average Rating of “Buy” by Brokerages

Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) has been assigned an average rating of “Buy” from the seven analysts that are presently covering the company, MarketBeat.com reports. One investment analyst has rated the stock with a hold recommendation, five have assigned a buy recommendation and one has assigned a strong buy recommendation to the company. The average 12 month price target among brokers that have covered the stock in the last year is $14.20.

AMRX has been the subject of a number of research analyst reports. Truist Financial raised their price target on shares of Amneal Pharmaceuticals from $15.00 to $17.00 and gave the stock a “buy” rating in a report on Monday, March 2nd. Weiss Ratings reissued a “hold (c)” rating on shares of Amneal Pharmaceuticals in a report on Wednesday, January 21st. Zacks Research upgraded Amneal Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research note on Friday, March 6th. Finally, Barclays started coverage on Amneal Pharmaceuticals in a research report on Monday, December 8th. They set an “overweight” rating and a $15.00 price target for the company.

Amneal Pharmaceuticals Stock Up 0.9%

Shares of Amneal Pharmaceuticals stock opened at $11.94 on Tuesday. The company has a 50 day moving average price of $13.77 and a 200 day moving average price of $12.03. The firm has a market capitalization of $3.75 billion, a P/E ratio of 51.92 and a beta of 1.34. Amneal Pharmaceuticals has a 52 week low of $6.68 and a 52 week high of $15.42.

Institutional Investors Weigh In On Amneal Pharmaceuticals

Institutional investors and hedge funds have recently modified their holdings of the company. Kemnay Advisory Services Inc. acquired a new position in Amneal Pharmaceuticals in the 4th quarter worth approximately $26,000. Federated Hermes Inc. raised its position in Amneal Pharmaceuticals by 1,680.6% during the 4th quarter. Federated Hermes Inc. now owns 2,297 shares of the company’s stock worth $29,000 after buying an additional 2,168 shares during the last quarter. Comerica Bank lifted its stake in Amneal Pharmaceuticals by 186.7% during the 3rd quarter. Comerica Bank now owns 3,005 shares of the company’s stock valued at $30,000 after acquiring an additional 1,957 shares during the period. Exchange Traded Concepts LLC purchased a new stake in shares of Amneal Pharmaceuticals in the 3rd quarter valued at $31,000. Finally, Spire Wealth Management boosted its holdings in shares of Amneal Pharmaceuticals by 66.6% in the 4th quarter. Spire Wealth Management now owns 2,558 shares of the company’s stock valued at $32,000 after acquiring an additional 1,023 shares during the last quarter. Institutional investors and hedge funds own 31.82% of the company’s stock.

Amneal Pharmaceuticals Company Profile

Amneal Pharmaceuticals, Inc is a publicly traded integrated healthcare company specializing in the development, manufacturing and distribution of generic and specialty pharmaceutical products. The company’s portfolio includes oral solids, injectables, transdermals and biosimilars, serving a broad range of therapeutic areas such as cardiovascular, neuroscience, oncology and women’s health. Alongside its generic offerings, Amneal has built a branded portfolio through strategic acquisitions and internal development, positioning itself across both high-volume generics and higher-value specialty treatments.

Since its founding in 2002 by brothers Chirag and Chintu Modgil, Amneal has pursued growth through organic investment in research and development as well as targeted M&A.